From Name:
From Email:
To Name:
To Email:

Optional Message:


Bevacizumab plus fosbretabulin improves survival in ovarian cancer

from The Oncology Report (Free login required)

The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic Cancer Society. A randomized, open-label, phase II study in 107 patients found a significant improvement in progression-free survival among patients treated with the combination of bevacizumab and fosbretabulin versus bevacizumab alone, with a median improvement of 2.5 months. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063